Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Inactivated influenza vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Inactivated influenza vaccine (split virion) | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: * Aged at least 18 years on the day of inclusion * Informed consent form signed * Able to attend all scheduled visits and to comply with all trial procedures * For a woman, inability to bear a child or negative urine pregnancy test at Visit 1 * For a woman of child-bearing poten...
Inactivated influenza vaccine is used for influenza, a viral infection of the respiratory tract. It is designed to prevent illness caused by influenza viruses. The vaccine is being studied in healthy adults to assess its ability to generate an immune response and its safety profile.
Sanofi (ticker: SNY) is developing Inactivated influenza vaccine. The company is conducting clinical research on this vaccine candidate for the prevention of influenza.
Inactivated influenza vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the vaccine is not currently in active trials.
Inactivated influenza vaccine has one completed Phase 2 trial, NCT00343681, titled "A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine." The trial enrolled 120 participants in Switzerland and the United Kingdom, all healthy adults aged 18 years and older.
No, Inactivated influenza vaccine is a vaccine, not a monoclonal antibody. It is designed to stimulate the immune system to produce a protective response against influenza viruses. The vaccine is being developed by Sanofi for the prevention of influenza.